Vicore Pharma Holding AB (publ)
Stockholm Stock Exchange VICO.ST
Vicore Pharma Holding AB (publ) Price to Earnings Ratio (P/E) on February 03, 2025: -6.05
-
Vicore Pharma Holding AB (publ) 52-week high Price to Earnings Ratio (P/E) is -5.20 on December 03, 2024, which is 13.96% above the current Price to Earnings Ratio (P/E).
-
Vicore Pharma Holding AB (publ) 52-week low Price to Earnings Ratio (P/E) is -16.99 on June 04, 2024, which is -180.91% below the current Price to Earnings Ratio (P/E).
-
Vicore Pharma Holding AB (publ) average Price to Earnings Ratio (P/E) for the last 52 weeks is -9.90.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
Don’t Miss A Beat
| CEO | Mr. Ahmed S. Mousa J.D. |
| IPO Date | Dec. 10, 2015 |
| Location | Sweden |
| Headquarters | Kronhusgatan 11 |
| Employees | 29 |
| Sector | Healthcare |
| Industries | |
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
Past 5 years
StockViz Staff
February 4, 2025
Any question? Send us an email